Fusion between P3 X 63 Ag8 mouse myeloma cells and spleen cells
mice immunized with influenza type A virus were directed against the viral hemagglutinin, one reacted with a host component derived from chickens, and one expressed a specificity not further characterized. The hybridoma antibodies tended to be highly specific for the hemagglutinin of the immunizing virus and seemed to express the same repertoire of strain-specific antibody reactivities as splenic precursor B cells specific for the hemagglutinin of the immunizing virus strain. However, in contrast to splenic precursor B cells, they did not express any of the frequently occurring crossreactive anti-hemagglutinin specificities. Hybridomas producing crossreactive antibodies against hemagglutinin could be obtained if priming and boosting virus were heterologous.
We have shown that somatic cell hybrids between mouse myeloma cells and spleen cells (hybridomas) from mice immunized with influenza virus produced antiviral antibodies (1) . The production of antibody by hybridomas has obvious advantages over the classic way of raising antisera in vivo, since hybridomas may provide large amounts of antibody of a desired specificity and homogeneous binding characteristics. Such antibodies, which are specific for individual antigenic determinants, should greatly facilitate antigenic analyses of complex substances. However, in order for antibody-producing somatic cell hybrids to be generally useful, it should be possible to obtain hybridomas expressing any possible antibody specificity and to maintain them for long periods of time in vitro or in vivo without incurring changes in their capacity to produce antibody or in the antibody specificity.
In the present study, we investigated the general feasibility of somatic cell hybridization for antiviral antibody production using spleen cells from mice immunized with influenza type A or B or parainfluenza type 1 virus for cell fusion. Furthermore, we analyzed hybridoma and splenic antiinfluenza antibody clones by means of an anti-idiotypic antiserum raised against the anti-PR8 antibodies produced by the hybridoma PEG-1 and compared the repertoire of antibody-binding specificities expressed by hybridomas to that expressed by splenic precursor B cells of BALB/c mice.
MATERIALS AND METHODS Virus. All virus strains were grown in the allantoic cavity of 10-day-old embryonated chicken eggs and were purified as described (2) . The Production of Hybrid Cells. The preparation of BALB/c spleen cells, the origin and growth properties of the myeloma parent cells (P3 X 63 Ag8), and the method of fusing spleen cells and myeloma cells in the presence of polyethylene glycol (PEG) or inactivated Sendai virus (5) were as described (1) . After fusion, cells were resuspended in hypoxanthine/aminopterin/ thymidine selective medium (6) and seeded in 75-cm2 Falcon flasks or in individual wells of Linbro plates FB16-24TC.
Cloning of Hybrid Cells. Initial hybrid cultures were cloned at limiting dilution in conditioned culture medium from P3 X 63 Ag8 myeloma cells or in soft agarose as described by Coffino and Scharff (7) but without a cellular feeder layer.
Splenic Fragment System. The production of monoclonal antibodies in the splenic fragment system has been described in detail (2) .
Radioimmunoassay. The assay was done as described (1) Production of Anti-PEG-i Anti-Idiotype Antiserum. Two New Zealand white rabbits were injected subcutaneously at multiple sites with 0.4 mg of PEG-1 antibodies in complete adjuvant H37Ra (Difco Laboratories, Detroit, MI). The rabbits were boosted twice at intervals of [4] [5] weeks with an intravenous injection of 0.1 mg of PEG-1 followed by an injection of 0.15 mg of Fab-(PEG-1). The rabbits were exsanguinated 14 days after the last injection. Antibodies directed against common Ig determinants were removed by precipitation of the serum with purified MOPC 21 (IgGi) and J606 (IgGS), the two isotypes secreted by the PEG-1 hybridoma (1). The adsorbed (anti-idiotype) serum was specific for idiotypic determinants of PEG-i antibodies (Fig. lb) .
Idiotype Competition Assay. The procedure described by Cancro et al. (11) Comparison of Hybridoma and Monoclonal Splenic Antibodies with Regard to Specificity of Combining Site and Idiotype. In order to determine whether the observed hybridoma antibody specificities represent frequently occurring specificities expressed by the secondary anti-PR8 precursor cell pool of the BALB/c mouse, the specificities of hybridoma antibodies and monoclonal splenic antibodies were compared ( Table 5 ). The splenic antibody clones were derived from the adoptive transfer of five individual BALB/c spleen cell preparations, obtained 4-6 months after animals were primed with PR8, into lethally irradiated syngeneic recipient mice. Splenic fragments of the recipients were stimulated in vitro with the homologous virus. This comparison is, therefore, only relevant for the H2 and H40 hybridomas (see Table 1 ) and for PEG-1, a hybridoma that produces anti-HA(PR8) antibody and has been described in detail (1) . In order to facilitate the comparison, antibodies are grouped in Table S on the basis of simplified reactivity type. Table 5 shows that 81% of the splenic monoclonal anti-PR8 antibodies are crossreactive, i.e., react with HA(PR8) and one or several heterologous HA (see legend of Table 5 ). This is in marked contrast to the predominant specificity of the hybridoma antibodies for the homologous HA. On the other hand, hybridoma antibodies seemed to express a repertoire of PR8-specific reactivity types similar to those of splenic antibody clones.
Table 5 also shows that none of the splenic antibody clones expressed the reactivity type of PEG-1. Thus, in order to verify the low frequency of antibodies with the reactivity type of PEG-1, all 96 splenic antibody clones were tested in the idiotype assay for the expression of PEG-1 idiotypic determinants. The (Fig. la) . These crossreactive idiotypic determinants were present in H53/1 mass culture fluid at roughly 10% lower concentration than in PEG-I culture fluid. However, none of the seven randomly selected hybridoma clones derived from H53/1 expressed an idiotype crossreactive with PEG-1.
Maintenance of Hybridomas, In order to obtain some information about the stability of hybridomas, clone 6 of hybridoma PEG-1 was passaged consecutively in ascitic form (2 X 105 cells intraperitoneally per passage) and in vitro (1:4-1:6 dilution of the culture every 2-3 days). Table 6 shows that in the course of in vvo and in vitro passages, PEG-I retained its capacity to produce antiviral antibodies. Furthermore, the reactivity type of the antibody did not change signficantly, as seen by its crossreaction with PR8-Mt.S and the PR8 variant V6. antibodies. This is surprising since the absolute frequency of secondary HA(PR8)-committed precursor B cells is roughly 1/5000 splenic B cells (2) and HA(PR8)-specific precursors (the splenic parent cells of the five antiviral antibody-producing hybrid cultures analyzed so far) represent approximately 20% of the total HA (PR8)-committed precursor cell pool, i.e., 1/ 25,000 splenic B cells (Table 5) In order to be of general usefulness, especially with regard to antigenic analyses, somatic cell hybrids should be able to express the complete repertoire of antibody specificities. This point was further investigated by comparing the specificities expressed by anti-HA(PR8) hybridomas with those expressed by monoclonal antibodies produced in the splenic fragment culture system (2, 8) . Analysis indicated that the hybridoma antibodies did express the same repertoire of strain-specific reactivity type as splenic antibodies. However, they obviously lacked the various crossreactive reactivity types which comprise roughly 80% of the splenic anti-HA(PR8) response. The reason for this discrepancy between the two systems is not known. It may be due to the different virus dose used for antigenic boost of the precursor cells in vivo and in vitro. It could also result from the possibility that a large fraction of hybridoma antibodies are monovalent with regard to their antiviral antibody binding activity and that many low-affinity crossreactions require bivalent antigen-antibody interactions to be detectable in the radioimmunoassay. it is also conceivable that specific and crossreactive precursors differ in their kinetics of differentiation after homologous antigenic boost and that only a certain stage of differentiation provides the B cell with the selective advantage in the process of fusion. However, one can exclude the possibility that certain subpopulations of the anti-HA(PR8) B cell repertoire are not at all susceptible to hybridization with the myeloma cell P3, since crossreactive hybrids were obtained when priming and boosting viruses were heterologous. The results reported here suggest that by using the right experimental conditions, the whole repertoire of anti-HA(PR8) antibody specificities may be obtained from antibody-producing hybrid clones.
DISCUSSION

